Zota Health Care Limited (NSE: ZOTA)
India
· Delayed Price · Currency is INR | Market Cap | 21.04B |
| Revenue (ttm) | 2.20B |
| Net Income (ttm) | -346.82M |
| Shares Out | 25.16M |
| EPS (ttm) | -13.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.00 (0.12%) |
| Ex-Dividend Date | Sep 20, 2024 |
| Volume | 43,625 |
| Open | 830.00 |
| Previous Close | 827.70 |
| Day's Range | 823.40 - 854.80 |
| 52-Week Range | 440.10 - 859.00 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 7, 2025 |
About Zota Health Care
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers generic drugs, wellness, over-the-counter products, ayurvedic products, and nutraceutical products. It provides various medicines for chronic ailments, such as diabetes, heart disease, and thyroid disorders. It operates its retail stores under the DAVAINDIA name. The company also exports its products. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India. [Read more]
Financial Performance
In 2023, Zota Health Care's revenue was 1.80 billion, an increase of 28.23% compared to the previous year's 1.41 billion. Losses were -143.48 million, 148.5% more than in 2022.
Financial StatementsNews
Zota Health Care secures product registration licenses for 12 products in Vietnam
Among the twelve products granted licenses, well-known drugs like Telmisartan, Etoricoxib, Levofloxacin, and Rosuvastatin are included. These products have been approved for a validity period of five ...
Zota Health Care expands Davaindia network to 1,294 stores, surpassing 600 COCO operational stores
Zota Health Care Limited has achieved a significant milestone in the expansion of its Davaindia network, with the total number of operational stores reaching 1,294 as of December 4, 2024. This marks a...